Paving the way to access to long-acting technologies

With the recent signing of the first MPP long-acting technologies voluntary licence, what should we consider in order to enhance access to long-acting therapeutics for HIV prevention and treatment, and why is it critical to anticipate potential access hurdles as early as possible?

**Moderators**

- Cherise Scott
  Unitaid

- Lobna Gaayeb
  Medicines Patent Pool

**Panelists**

- **Prof. Quarraisha Abdool Karim**
  CAPRISA
  Key considerations for enhancing access to long-acting technologies

- **Dr. N Kumarasamy**
  Clinton Health Access Initiative
  Considerations for inclusion of all populations throughout the product lifecycle, including pregnant individuals and children

- **Yves Kugbe**
  Long-Acting Technologies Community Advisory Board
  Reflections from the first global community advisory board focused on long-acting technologies

- **Siobhan Crowley**
  The Global Fund
  Determinants for successful roll-out and uptake

**Concluding remarks**

- **Sandra Nobre**
  Head of Business Development
  Medicines Patent Pool